The FDA has approved label extensions for two of the most crucial cancer medications globally—Merck’s Keytruda and Pfizer and Astellas’ Xtandi. Keytruda’s expanded indication now includes stomach cancer, permitting its usage alongside chemotherapy for first-line treatment in patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Xtandi’s expanded approval broadens its comprehensive portfolio in prostate cancer treatment. It is now the sole androgen receptor inhibitor sanctioned by the FDA for patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) experiencing biochemical ...
